# A Study on the Efficacy and Safety of IPyC for HER2+ MBC

> **NCT06990347** · — · COMPLETED · sponsor: **Fujian Medical University** · enrollment: 301 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Inetetamab and Pyrotinib Combined with Chemotherapy

## Key facts

- **NCT ID:** NCT06990347
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990347, "A Study on the Efficacy and Safety of IPyC for HER2+ MBC". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06990347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*